Biohaven Pharma (BHVN) Tops Q2 EPS by 31c

Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($1.63), $0.31 better than the analyst estimate of ($1.94).

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Apple suing OpenAI over alleged misappropriation of trade secrets
• GuideAI Health hires firms for marketing and investor outreach
• Discovery Energy Metals plans private placement of up to $1.25M